# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy rati...
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that three poster presentations will be delivered during the 84th S...
Needham analyst Joseph Stringer reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Hold.
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. ...
Leerink Partners initiates coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Outperform rating and announces Price Tar...
Needham analyst Joseph Stringer reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Hold.